Last $62.62 USD
Change Today +0.85 / 1.38%
Volume 159.6K
CRL On Other Exchanges
Symbol
Exchange
New York
Berlin
As of 3:36 PM 12/17/14 All times are local (Market data is delayed by at least 15 minutes).

charles river laboratories (CRL) Snapshot

Open
$61.84
Previous Close
$61.77
Day High
$62.89
Day Low
$61.49
52 Week High
11/3/14 - $66.11
52 Week Low
05/2/14 - $49.60
Market Cap
2.9B
Average Volume 10 Days
288.8K
EPS TTM
$2.66
Shares Outstanding
46.9M
EX-Date
--
P/E TM
23.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for CHARLES RIVER LABORATORIES (CRL)

charles river laboratories (CRL) Related Bloomberg News

View More Bloomberg News

charles river laboratories (CRL) Related Businessweek News

No Related Businessweek News Found

charles river laboratories (CRL) Details

Charles River Laboratories International, Inc., together with its subsidiaries, provides research models and associated services, and outsourced preclinical services to accelerate the drug discovery and development process. It operates through two segments, Research Models and Services (RMS), and Preclinical Services (PCS). The RMS segment produces and sells research model strains, principally genetically and microbiologically defined purpose-bred rats and mice for use by researchers. This segment also offers a range of services to assist customers in the drug discovery and development process, which include genetically engineered models and services, insourcing solutions, discovery research services, and research animal diagnostic services; endotoxin and microbial detection products and services; and avian vaccine products and services. The PCS segment provides preclinical services, including in vivo and in vitro studies, supporting laboratory services, and strategic preclinical consulting and program management to support product development. This segment offers services in the areas of bioanalysis, pharmacokinetics, and drug metabolism; toxicology; and pathology services, as well as testing of biologics and devices frequently outsourced by pharmaceutical and biotechnology companies. The company serves pharmaceutical companies, biotechnology companies, government agencies, hospitals, and academic institutions worldwide. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.

7,700 Employees
Last Reported Date: 02/25/14
Founded in 1947

charles river laboratories (CRL) Top Compensated Officers

Chairman, Chief Executive Officer, President,...
Total Annual Compensation: $1.1M
Chief Financial Officer and Corporate Executi...
Total Annual Compensation: $512.2K
Corporate Executive Vice President and Presid...
Total Annual Compensation: $450.9K
Chief Scientific officer and Corporate Execut...
Total Annual Compensation: $500.5K
Corporate Executive Vice President of Global ...
Total Annual Compensation: $400.5K
Compensation as of Fiscal Year 2013.

charles river laboratories (CRL) Key Developments

Charles River Laboratories International Announces Management Changes

Charles River Laboratories International, Inc. announced that Jrg Geller, Corporate Executive Vice President, Global Productivity and Efficiency, had announced his intention to retire in March 2015. Geoff Goldsmith, Corporate Vice President, North American Operations Optimization, will continue in his role with Charles Rivers global productivity and efficiency initiatives with support from other individuals globally.

Charles River Laboratories International, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months of 2014; Revises Earnings Guidance for the Year 2014; Provides Earnings Guidance for the Fourth Quarter of 2014

Charles River Laboratories International, Inc. reported unaudited consolidated earnings results for the third quarter and nine months of 2014. For the quarter, the company's revenue from continuing operations was $327.6 million, an increase of 12.1% from $292.1 million in the third quarter of 2013. Revenue growth was driven by the acquisition of Argenta and BioFocus, which was completed on April 1, 2014 and contributed 8.0% to third-quarter revenue, as well as double-digit growth in the Manufacturing Support segment. Foreign currency translation benefited reported revenue by 0.4%. Net income from continuing operations was $32.3 million, or $0.68 per diluted share, compared to $31.3 million, or $0.64 per diluted share, for the third quarter of 2013. Non-GAAP net income from continuing operations was $40.4 million, an increase of 5.7% from $38.2 million for the same period in 2013. Non-GAAP earnings per share were $0.86, an increase of 8.9% compared to $0.79 per share in the third quarter of 2013. Higher sales, a lower tax rate and the benefit of stock repurchases contributed to the earnings per share increase. A loss of $0.01 per share on the company's limited partnership investments was offset by miscellaneous other items. Operating income was $46.172 million against $40.843 million a year ago. Income from continuing operations before income taxes was $43.882 million against $42.726 million a year ago. Net income attributable to common shareowners was $32.036 million against $30.867 million a year ago. Diluted earnings per common share were $0.68 against $0.64 a year ago. Capital expenditures were $9.402 million against $9.096 million a year ago. Operating income. excluding specified charges (non-GAAP) was $58.161 million against $54.146 million a year ago. For the nine months, the company's revenue increased by 10.5% to $968.1 million from $876.3 million in the same period in 2013. The acquisition of Argenta and BioFocus contributed 5.3% to year-to-date revenue, and foreign currency translation benefited reported revenue by 0.8%. Net income from continuing operations was $101.4 million, or $2.11 per diluted share, compared to $85.9 million, or $1.75 per diluted share, for the same period in 2013. Non-GAAP net income from continuing operations was $126.0 million, or $2.65 per diluted share, compared to $107.1 million, or $2.20 per diluted share, for the same period in 2013. Operating income was $136.903 million against $126.794 million a year ago. Income from continuing operations before income taxes was $137.409 million against $115.221 million a year ago. Net income attributable to common shareowners was $99.532 million against $83.729 million a year ago. Diluted earnings per common share were $2.09 against $1.72 a year ago. Capital expenditures were $29.907 million against $25.319 million a year ago. Operating income. excluding specified charges (non-GAAP) was $173.940 million against $153.977 million a year ago. Net cash provided by operating activities was $152.283 million against $146.550 million a year ago. In the fourth quarter, the company anticipates that normal seasonal trends will result in revenue, operating margin and EPS below the third quarter levels. The softer seasonal sales volume is expected to have a more pronounced impact on the RMS segment, consistent with historical trends. In recent years, the RMS segment's operating margin has dipped below 25% in the fourth quarter, and the company also expects this to occur in 2014. For the year 2014, the company expects reported net revenue growth between 10.0% to 11.0%, net revenue growth at constant currency between 10.0% to 11.0%, GAAP EPS estimate between $2.65 to $2.70 and non-GAAP EPS estimate between $3.33 to $3.38 against previously expected reported net revenue growth between 9.0% to 11.0%, net revenue growth at constant currency between 9.0% to 11.0%, GAAP EPS estimate between $2.60 to $2.70 and non-GAAP EPS estimate between $3.25 to $3.35. The company expects operating losses and other items of $0.06 and amortization of intangible assets of $0.39 against previously expected operating losses and other items of $0.06 and amortization of intangible assets of $0.36. The company now expect 2014 net interest expense to be $11.5 million to $12 million, which is below prior outlook of $12 million to $14 million, due primarily to debt repayment in the third quarter. This revised outlook includes a small amount of interest expense associated with the ChanTest acquisition for the final 2 months of 2014. With a year-to-date tax rate of 27.2%, the company have narrowed non-GAAP tax rate outlook to a range of 27% to 27.5% for 2014. The company currently expect 2014 free cash flow to be in a range of $180 million to $185 million, which represents an increase of $10 million to $15 million over 2013. This is at the lower end of previous range of $180 million to $190 million, due to higher-than-expected DSOs and additional cash expenses such as severance and acquisition-related cost. The company has revised capex estimate to the lower end of previous range of $55 million to $60 million for the year due to timing.

Charles River Laboratories International, Inc. to Report Q3, 2014 Results on Oct 29, 2014

Charles River Laboratories International, Inc. announced that they will report Q3, 2014 results at 5:00 PM, Eastern Standard Time on Oct 29, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CRL:US $62.62 USD +0.85

CRL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Covance Inc $102.60 USD +0.55
Ergomed PLC 152.50 GBp 0.00
ICON PLC $51.97 USD +0.77
PAREXEL International Corp $53.61 USD +0.46
WuXi PharmaTech Cayman Inc $32.79 USD -0.2311
View Industry Companies
 

Industry Analysis

CRL

Industry Average

Valuation CRL Industry Range
Price/Earnings 24.8x
Price/Sales 2.3x
Price/Book 4.3x
Price/Cash Flow 20.5x
TEV/Sales 1.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CHARLES RIVER LABORATORIES, please visit www.criver.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.